Stem Cell Safety and Red Flags

The stem cell field has two very different safety records depending on where a treatment sits. Approved, rigorously regulated products such as cord-blood hematopoietic transplants have decades of monitored outcome data and well-characterized risks. Unapproved products sold direct-to-consumer by clinics outside a registered clinical trial have a much thinner and considerably more troubling safety record, and this page focuses on that second category.

The most systematic documentation of harm comes from the Pew Charitable Trusts, which published an issue brief in 2021 identifying roughly 360 adverse events connected to unapproved stem cell interventions in the United States between 2004 and 2020, drawn from FDA reports, medical literature, and news coverage [1]. A companion peer-reviewed paper in Regenerative Medicine detailed the same dataset and argued for stronger FDA enforcement against the direct-to-consumer stem cell marketplace [2]. Reported harms in this body of work ranged from infections and tumor-like growths to permanent injury; the most widely cited case involved three patients who were blinded after receiving unapproved adipose-derived stem cell injections directly into the eye for age-related macular degeneration, a case detailed on our FDA regulation page [3]. This dataset has drawn some criticism for potentially over-representing severe, newsworthy cases relative to the full population of stem cell clinic patients, since routine, uneventful treatments are less likely to generate a case report or news story in the first place; the true rate of harm per procedure performed is not precisely known.

The International Society for Stem Cell Research publishes a patient handbook specifically to help people evaluate a stem cell treatment offer before committing to it [4]. The handbook sorts treatments into three categories: approved treatments that have cleared a national regulatory review process for a specific use, investigational treatments being studied in a properly registered and monitored clinical trial, and unproven treatments being sold without adequate evidence or regulatory clearance [4]. It flags specific marketing patterns as red flags, including a single clinic or product being promoted as a treatment for many unrelated diseases, patient testimonials used as the primary evidence of effectiveness, requiring the patient to pay the full cost out of pocket for something described as part of a clinical trial, and vague sourcing language about where the cells come from or how they are processed [4].

Beyond the direct-to-consumer marketplace, the broader clinical trial safety literature offers useful context on how MSC therapy behaves when given properly. A 2021 meta-analysis of 62 randomized controlled trials spanning about 20 disease categories and 3,546 total participants found no signal of serious adverse events like death or infection attributable to MSC administration overall, but did find statistically higher rates of transient fever, injection-site reactions, constipation, fatigue, and sleep disturbance in treated groups [5]. Separately, MSCs are known to express tissue factor, a procoagulant protein, which has raised a specific and mechanistically plausible concern about thromboembolic risk when MSCs are given intravenously rather than by local injection, an issue reviewed in dedicated literature on this exact risk [6].

Practical checklist for evaluating any stem cell offer: verify whether the product has completed FDA or EMA review for the specific condition being treated, ask for the specific clinical trial registration number if the clinic describes the treatment as investigational, be skeptical of any program treating more than one or two unrelated conditions with the same product, and treat patient testimonials as marketing rather than evidence. None of the disease-specific pages in this encyclopedia section describe an approved, over-the-counter stem cell treatment; every therapy discussed here is either fully regulated hospital-based care such as bone marrow transplant, or investigational and still under study.

This page itself functions as a safety reference rather than an evidence-tiered treatment claim, so it does not carry an evidence tier in the same sense as a disease page; readers should treat every specific numeric claim above as tied to its own cited source rather than to a single overall grade.

FDA enforcement against unapproved stem cell clinics continued in August 2026. On August 25, 2026, FDA posted a warning letter to R3 Medical Companies of Scottsdale, Arizona, and its CEO David L. Greene, M.D. (CBER 26-726330), issued August 14, 2026, after facility inspections of Bello Bio, LLC and Regen Suppliers, LLC between November 17 and December 16, 2025 [7]. The letter covers four umbilical-cord-derived and exosome products sold under the ReBella line (ReBellaWJ, ReBellaXO, ReBellaXOL, ReBellaCB) and finds them unapproved new drugs under 21 U.S.C. 355(a) and unlicensed biological products under 42 U.S.C. 262(a)(1), with no approved biologics license application or investigational new drug application in effect. FDA also charged adulteration under 21 U.S.C. 351(a)(2)(B) based on CGMP violations: unvalidated aseptic processing for products marketed as sterile, sterility samples frozen before testing, a 24-month expiration date set without stability data, and a quality unit with no written procedures. The same CEO received an earlier untitled letter for R3 Stem Cell, LLC, meaning FDA has now acted against David Greene's operations across multiple corporate entities over several years. On August 28, 2026, the US District Court for the Central District of California entered a permanent injunction against California Stem Cell Treatment Center, Inc., Cell Surgical Network Corporation, and Dr. Elliot B. Lander [8]. The order covers stromal vascular fraction (SVF), cells obtained or derived from adipose tissue, expanded SVF products including ATCELL, and products combining SVF with other articles. The defendants must obtain FDA written notification before resuming covered operations. The case ran from 2018: FDA lost at district court in 2022, won on appeal, and returned to Judge Bernal for the injunction. Cell Surgical Network had been one of the largest SVF clinic networks in the country.